Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT02949193
- Locations
- 🇰🇷
Kangbuk Samsung Medical Center, Seoul, Korea, Republic of
Treatment of Diabetes in Patients With Systolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 36
- Registration Number
- NCT02920918
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 348
- Registration Number
- NCT02917031
- Locations
- 🇺🇦
Research Site, Rivne, Ukraine
Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 9
- Registration Number
- NCT02900417
HbA1c Variability in Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Weill Cornell Medical College in Qatar
- Target Recruit Count
- 150
- Registration Number
- NCT02879409
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 504
- Registration Number
- NCT02849080
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Rize, Turkey
The Effect of DPP4 Inhibitor on Vasclular Healing
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Chung-Ang University
- Target Recruit Count
- 66
- Registration Number
- NCT02802644
- Locations
- 🇰🇷
Keimyung University Hospital, Daegu, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Chung-Ang University Hospital, Seoul, Korea, Republic of
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 458
- Registration Number
- NCT02791490
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Michael A. Nauck
- Target Recruit Count
- 24
- Registration Number
- NCT02749032
- Locations
- 🇩🇪
Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, Germany
Drug Transporter Interaction Study PHENTRA_2015_KPUK
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 24
- Registration Number
- NCT02743260
- Locations
- 🇩🇪
Department of Pharmacology I, University Hospital Cologne, Cologne, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.